Clinical Trial Update: Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of doxorubicin and bevacizumab in patients with locally recurrent or metastatic soft tissue sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Adriamycin (doxorubicin)
• Avastin (bevacizumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sarcoma | Phase 2 | Status: COMPLETED